31 Mar SAHPRA assigns a non-compliant rating to the Emergent BioSolutions COVID-19 facility
31 March 2022
SAHPRA has assigned a non-compliant rating to the Emergent BioSolutions COVID-19 facility based on new data received. This was following a collaborative inspection which was conducted both onsite and via remote inspection. This means that SAHPRA will not accept any drug products or drug substances manufactured at this facility until another Good Manufacturing Practice (GMP) inspection is completed, and the facility meets GMP requirements. None of the Janssen COVID-19 vaccines available in South Africa contains ingredients made at this facility.